Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort

Objectives: Osimertinib is a third-generation EGFR inhibitor with activity against both sensitizing and resistance mutations. Following results of the phase III study, AURA3, which led to the approval of osimertinib worldwide, we have conducted ASTRIS with the aim of confirming the effica...

Full description

Saved in:
Bibliographic Details
Main Authors: Luiz Henrique Araujo, Gilberto de Castro, Clarissa Baldotto, Marcelo Graziano Custódio, Pedro De-Marchi, Aknar Calabrich, Clarissa Mathias, André Santa-Maria, Maíra Takemoto, Helano Freitas
Format: Article
Language:English
Published: Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia 2020-01-01
Series:Brazilian Journal of Oncology
Subjects:
Lung neoplasms
Genes
erbB-1
Molecular targeted therapy
Neoplasias pulmonares
Genes erbB-1
Terapia direcionada molecular
Online Access:http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20200005
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20200005

Similar Items